Table 2.
Univariable | Multivariable | |||||
---|---|---|---|---|---|---|
OR | 95% CI | P-value | OR | 95% CI | P-value | |
PSMA-TV (cm3) | 1.00 | 1.00–1.00 | 0.77 | |||
TL-PSMA (cm3) | 1.00 | 1.00–1.00 | 0.18 | |||
SUVMean | 1.18 | 1.06–1.33 | 0.004 | 1.18 | 1.05–1.35 | 0.008 |
SUVPeak | 1.02 | 1.00–1.04 | 0.08 | |||
SUVMax | 1.00 | 1.00–1.01 | 0.27 | |||
visceral metastases | 0.97 | 0.42–2.26 | 0.95 | |||
liver metastases | 0.80 | 0.28–2.24 | 0.67 | |||
PSA µg/l | 1.00 | 1.00–1.00 | 0.08 | |||
CRP mg/dl | 0.86 | 0.74–0.97 | 0.03 | 0.97 | 0.82–1.12 | 0.71 |
LDH (37 °C U/l) | 0.995 | 0.99–0.999 | 0.01 | 0.99 | 0.99–0.999 | 0.07 |
Hemoglobin g/dl | 1.30 | 1.02–1.70 | 0.04 | 1.13 | 0.83–1.55 | 0.45 |
AST (37 °C U/l) | 0.99 | 0.98–1.01 | 0.51 | |||
AP (37 °C U/l) | 1.00 | 0.99–1.00 | 0.81 | |||
Age at 1st cycle | 1.07 | 1.01–1.14 | 0.02 | 1.07 | 1.00–1.14 | 0.04 |
Time period between initial diagnosis and 1st RLT (months) | 1.01 | 1.00–1.02 | 0.02 | |||
Prior CTx | 0.51 | 0.18–1.36 | 0.18 | |||
Gleason | 0.75 | 0.47–1.18 | 0.22 |
OR odds ratio, CI confidence interval, PSMA-TV PSMA-positive tumor volume, TL-PSMA total lesion PSMA, SUV standardized uptake value, PSA prostate-specific antigen, CRP C-reactive protein, LDH lactate dehydrogenase, AST aspartate aminotransferase, AP alkaline phosphatase, IntervalDiagnosis-RLT time period between initial diagnosis and 1st RLT, CTx chemotherapy. Significant values are marked in bold